NCT01075308 - SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2010

Primary Completion Date

January 5, 2015

Study Completion Date

February 13, 2015

Conditions

Prostate Cancer

Interventions

DRUG

HDAC inhibitor SB939

SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).

Trial Locations (7)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

B3H 1V7

QEII Health Sciences Center, Halifax

N6A 4L6

London Regional Cancer Program, London

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto